Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study.
Santin A, Graf R, Shah K, Kelly A, Danziger N, Lin D, Oxnard G, Elvin J. Biomarker associations of immune checkpoint inhibitor versus chemotherapy effectiveness in first-line metastatic endometrial carcinomas: A real-world study. Journal Of Clinical Oncology 2022, 40: 5596-5596. DOI: 10.1200/jco.2022.40.16_suppl.5596.Peer-Reviewed Original ResearchSingle-agent immune checkpoint inhibitorsImmune checkpoint inhibitorsTumor mutational burdenCheckpoint inhibitorsMEC patientsChemotherapy effectivenessMSI statusAnti-PD1 immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsMultivariable Cox proportional hazards modelsCox proportional hazards modelMetastatic endometrial carcinomaOverall survival comparisonEndometrial carcinoma patientsMut/MbProportional hazards modelReal-world studyPrespecified analysis planHazard ratioStandard chemotherapyCarcinoma patientsEndometrial carcinomaPredictive biomarkersChemotherapy treatmentFavorable outcomeRandomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.Peer-Reviewed Original ResearchConceptsPrimary peritoneal cancerPeritoneal cancerPredictive biomarkersDay 1Taxane-resistant ovarian cancerPhase II trialM2 days 1Bevacizumab 10Evaluable patientsPrior bevacizumabWeekly ixabepiloneII trialPrimary endpointSecondary endpointsRefractory statusTUBB3 expressionPrior receiptSubgroup analysisClinical trialsOvarian cancerIxabepilonePFSCancerBevacizumabPatients